Global Urinary Tract Infection Treatment Market 2017-2021


◆タイトル:Global Urinary Tract Infection Treatment Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。


当調査レポートでは、尿路感染症(UTI)治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、尿路感染症(UTI)治療の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、製品パイプライン分析、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は尿路感染症(UTI)治療の世界市場が2017-2021年期間中に年平均2.15%成長すると予測しています。当レポート上に記載されている主な企業は• Merck, • Bayer,• Johnson & Johnson,• Novartis等です。



About Urinary Tract Infection TreatmentUTI is an infection occurred in any part of the urinary system. The infection mostly involves the lower part of the urinary tract. UTI can be classified into different types depending on the portion of the urinary system affected. Women are comparatively at a higher risk of developing UTI as compared with men since the urethra of the women is comparatively smaller than men and is also closer to the anus. This anatomical structure of the urinary tract in women increases the chances of transfer of the bacteria to the bladder. However, people of any sex and age can get affected by the disease.

Technavio’s analysts forecast the global urinary tract infection treatment market to grow at a CAGR of 2.15% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global urinary tract infection treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, off-label, and generic drugs.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Urinary Tract Infection Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Merck,
• Bayer,
• Johnson & Johnson,
• Novartis

[Other prominent vendors]
• Achaogen
• Allergan
• Aquinox Pharmaceuticals
• AstraZeneca
• Lipella Pharmaceuticals
• MediciNova
• MerLion Pharma
• Mylan
• Novo Nordisk
• Shionogi
• Sun Pharmaceuticals
• Teva Pharmaceutical Industries
• Urigen
• Zavante Therapeutics

[Market driver]
• Relation of UTI with several other factors leading to rising incidence rate of UTI
• For a full, detailed list, view our report

[Market challenge]
• Development of antibacterial resistance
• For a full, detailed list, view our report

[Market trend]
• Growing awareness of controlled usage of antibiotics
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Pipeline analysis

PART 07: Market segmentation by disease type
• Uncomplicated UTI
• Complicated UTI

PART 08: Geographical segmentation
• UTI treatment market in Americas
• UTI treatment market in EMEA
• UTI treatment market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Growing awareness of controlled usage of antibiotics
• Rising R&D for effective treatment against superbugs/MDR microorganisms
• Advent of new therapies for UTI treatment

PART 12: Vendor landscape

PART 13: Key vendor analysis
• Bayer
• Johnson & Johnson
• Merck
• Novartis
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: UTI in various parts of the urinary tract
Exhibit 02: Symptoms, diagnosis, and treatment of UTI
Exhibit 03: Common medications used for the treatment of UTI
Exhibit 04: Global UTI treatment market snapshot
Exhibit 05: Global UTI treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of global UTI treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Key pipeline molecules by vendors
Exhibit 09: Global UTI treatment market: Key clinical trials
Exhibit 10: Segmentation of global UTI treatment market by disease type 2016
Exhibit 11: Causative organisms for uncomplicated UTI
Exhibit 12: Global uncomplicated UTI treatment market 2016-2021 ($ millions)
Exhibit 13: Risk factors for uncomplicated UTI
Exhibit 14: Management of uncomplicated UTI through antimicrobial agents
Exhibit 15: Causative organisms for complicated UTI
Exhibit 16: Global complicated UTI treatment market 2016-2021 ($ millions)
Exhibit 17: Risk factors for complicated UTI
Exhibit 18: Segmentation of global UTI treatment market based on geography 2016 and 2021
Exhibit 19: Global UTI treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 20: Market scenario in Americas
Exhibit 21: UTI treatment market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: UTI treatment market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: UTI treatment market in APAC 2016-2021 ($ millions)
Exhibit 26: Major factors contributing to UTI
Exhibit 27: New cases of diabetes by 2040
Exhibit 28: Accepted indications for catheter use
Exhibit 29: Major causes of antibiotic resistance
Exhibit 30: Competitive structure analysis of global UTI treatment market 2016
Exhibit 31: Bayer: Key highlights
Exhibit 32: Bayer: Strength assessment
Exhibit 33: Bayer: Strategy assessment
Exhibit 34: Bayer: Opportunity assessment
Exhibit 35: Johnson & Johnson: Key highlights
Exhibit 36: Johnson & Johnson: Strength assessment
Exhibit 37: Johnson & Johnson: Strategy assessment
Exhibit 38: Johnson & Johnson: Opportunity assessment
Exhibit 39: Merck: Key highlights
Exhibit 40: Merck: Strength assessment
Exhibit 41: Merck: Strategy assessment
Exhibit 42: Merck: Opportunity assessment
Exhibit 43: Novartis: Key highlights
Exhibit 44: Novartis: Strength assessment
Exhibit 45: Novartis: Strategy assessment
Exhibit 46: Novartis: Opportunity assessment


Merck, Bayer, Johnson & Johnson, Novartis, Achaogen, Allergan, Aquinox Pharmaceuticals, AstraZeneca, Lipella Pharmaceuticals, MediciNova, MerLion Pharma, Mylan, Novo Nordisk, Shionogi, Sun Pharmaceuticals, Teva Pharmaceutical Industries, Urigen, and Zavante Therapeutics.


尿路感染症、 尿路感染症治療